Influenza virus delta NS1 vaccine

Drug Profile

Influenza virus delta NS1 vaccine

Alternative Names: deltaFLU LAIV; deltaFLU quadrivalent LAIV; FluVacc; FluVacc - DNS1; Fluvacc delta NS1; FLUVACCdelNS1; FluVaccΔNS1; GHB01L1; GHB04L1; GHB11L1; GHB16L2; H5N1 influenza virus vaccine; Influenza A virus vaccine H1N1; Intranasal H5N1 vaccine - Avir Green Hills Biotechnology; Pandemic avian flu vaccine - Avir Green Hills Biotechnology; Seasonal influenza vaccine deltaFLU; Seasonal influenza virus vaccine Green Hills - Biotechnology

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator Green Hills Biotechnology
  • Developer Vivaldi Biosciences
  • Class Antivirals; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 06 Aug 2015 Phase-II development is ongoing in Austria
  • 10 Oct 2013 Vivaldi Biosciences acquires research and development assets for delta-NS1 live attenuated influenza vaccines
  • 15 Nov 2011 AVIR Green Hills Biotechnology terminates a phase II trial for Influenza virus infections in United Kingdom (EudraCT2009-011529-15)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top